213 related articles for article (PubMed ID: 33877088)
1. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
2. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.
Galeone C; Bruzzi P; Jommi C
BMJ Open; 2021 Jan; 11(1):e041259. PubMed ID: 33441356
[TBL] [Abstract][Full Text] [Related]
3. Using GRADE methodology to assess innovation of new medicinal products in Italy.
Fortinguerra F; Tafuri G; Trotta F; Addis A
Br J Clin Pharmacol; 2020 Jan; 86(1):93-105. PubMed ID: 31656055
[TBL] [Abstract][Full Text] [Related]
4. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
5. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
6. The Assessment of the Innovativeness of a New Medicine in Italy.
Fortinguerra F; Perna S; Marini R; Dell'Utri A; Trapanese M; Trotta F;
Front Med (Lausanne); 2021; 8():793640. PubMed ID: 34957163
[No Abstract] [Full Text] [Related]
7. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
Mammarella F; Tafuri G
Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
[TBL] [Abstract][Full Text] [Related]
8. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
[TBL] [Abstract][Full Text] [Related]
9. Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Gori S; Di Maio M; Pinto C; Alabiso O; Baldini E; Barbato E; Beretta GD; Bravi S; Caffo O; Canobbio L; Carrozza F; Cinieri S; Cruciani G; Dinota A; Gebbia V; Giustini L; Graiff C; Molino A; Muggiano A; Pandoli G; Puglisi F; Tagliaferri P; Tomao S; Venturini M;
Tumori; 2011; 97(4):442-8. PubMed ID: 21989431
[TBL] [Abstract][Full Text] [Related]
10. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
11. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
13. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
[TBL] [Abstract][Full Text] [Related]
14. A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines.
Garsen M; Steenhof M; Zwiers A
Ther Innov Regul Sci; 2021 Jul; 55(4):633-642. PubMed ID: 33543409
[TBL] [Abstract][Full Text] [Related]
15. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
16. EU marketing authorization review of orphan and non-orphan drugs does not differ.
Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
[TBL] [Abstract][Full Text] [Related]
17. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
18. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006-2015: a cohort study.
Boucaud-Maitre D; Altman JJ
Eur J Clin Pharmacol; 2016 Oct; 72(10):1275-1281. PubMed ID: 27473682
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
[TBL] [Abstract][Full Text] [Related]
20. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
